Skip to main content

Table 5 Summary of percent filtered glucose excreted in urine on day 2 by treatment

From: Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus

  Met BID RE BID Met + RE BID
N = 13 N = 13 N = 13
Mean (SD) 1.41 (1.52) 51.3 (7.02) 48.7 (9.87)
Median 0.95 51.8 49.3
Min, Max 0.10, 4.71 38.4, 61.3 35.7, 67.9